ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IDXX / forecast
LNTH (76) ORKA (53) NEOG (47) CLDX (29) ⌘ Pro Terminal →

IDEXX Laboratories Inc. (IDXX) 12-Month Stock Forecast & Price Target Cone

$671.64 +21.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $699.67

IDEXX Laboratories Inc. (IDXX) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (61.8% gross margin, 30% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- • BUY Cap $43.42B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IDXX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IDXX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, IDEXX Laboratories Inc. (NASDAQ: IDXX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $671.64 (+21.85% 1D, market cap $43.42B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, IDXX ranks #72 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IDXX compare to LNTH and ORKA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), IDXX carries a Roarable B- (70/100 RQD), trailing P/E of 42.8x, gross margin of 61.8%, and ROIC of 29.6%. By comparison, LNTH (Lantheus Holdings Inc.) holds a B+ grade (76/100 RQD, P/E 28.0x, ROIC 20.3%, cap $6.56B) and ORKA (Oruka Therapeutics Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -18.8%, cap $6.41B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while IDXX leads on capital efficiency (29.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IDXX?
▼

Per IDXX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000874716), IDEXX Laboratories Inc. generated $4.30B in revenue (+10.4% YoY), $1.06B in net income, and $1.06B in free cash flow against $3.35B in total assets and $374.8M in total debt. Key quantitative strengths: Strong cash generator (61.8% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $699.65 (+4.17%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 24.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 70/100 (B-) historically ranked in the Top 15% of excess returns over the next 90 days (+6.6% avg 90D alpha vs SPY • 68.1% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B-
025507510070
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B- · Rk B-
Cash (19)Whales (10)SEC (18)Macro (10)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+5.4% Base Target
$835 Bull$708 Base$551 Bear
📬 FREE IDXX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IDXX)Realized 20D OHLCV Swing Band: ±5.4%
Deterministic 5-Pillar Attribution (70/100 Composite)
🔍 WHY IDXX SCORES 70/100 (B-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 24.6% FCF Margin ($1.06B FCF) & 61.8% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (26% of score)

Altman Z-Score 20.99 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Macro Regime Fit10/20 pts (-10 pt drag)

Macro rate sensitivity & RSI-14 (50.5) create a -10 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
62
Grade C+$529.01+4.6% Next Q
Q2 (-2Q)
65
Grade C+$553.48+1.7% Next Q
Q3 (-1Q)
67
Grade B-$562.91+19.3% Next Q
Current
70
Grade B-$671.64+6.6% Hist 90D α
Trajectory: C+ (62) → B- (70)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the IDXX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 70/100 (B-) score, IDXX faces multiple-compression risk if 42.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($535.00) or 200D SMA ($570.57) invalidates the momentum regime and cuts Target Base ($707.91) toward Bear Floor ($550.74).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IDXX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IDXX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 70%NO 30%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your IDXX Position Size: $10,000

Shares at $671.64: 14.9 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $550.74
$8,200
$-1,800 (-18.0%)
12M Consensus BaseTarget $707.91
$10,540
+$540 (+5.4%)
12M Bull Case BreakoutTarget $835.33
$12,437
+$2,437 (+24.4%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (34 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 23● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskOUTPERFORM$73674%A
Goldman SachsSector Coverage LeadBUY$78569%B
JP MorganUS Large-Cap ResearchHOLD$62958%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (IDXX Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IDXX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +19.27%📐 HORIZONTAL RANGE
2026-11-03O $576.0H $671.6L $551.2C $671.6VOL 1.17M
RES: $697.2SUP: $490.2SMA50: $535.0SMA200: $570.6
$683.6$634.0$584.4$534.8$485.2RES $697.2SUP $490.2$671.62026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IDXX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IDXX Butterfly Map → + Track IDXX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
32.2%/yr Implied 5Y Growth

vs. +10.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IDXX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IDXX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IDXX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IDXX)

Health Care Rank #72 of 1015 ⚔️ LNTH vs IDXX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IDXX vs. LNTH, ORKA, NEOG, CLDX)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, IDEXX Laboratories Inc. (IDXX) ranks #72 by composite RQD confidence (70/100, grade B-) and #42 by equity capitalization ($43.42B). Within this direct 5-issuer industry benchmark cohort, LNTH leads on earnings valuation at 28.0x trailing P/E, while IDXX leads on capital efficiency and profitability with 29.6% ROIC and 61.8% gross margin. LNTH currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with IDXX at 70/100 (B-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IDXX ACTIVE
IDEXX Laboratories Inc.
B- 70/100 42.8x 61.8% 29.6% +21.85% $43.42B Benchmark Subject
LNTH
Lantheus Holdings Inc.
B+ 76/100 28.0x 61.1% 20.3% -0.15% $6.56B /lnth-vs-idxx →
ORKA
Oruka Therapeutics Inc.
D+ 53/100 — — -18.8% -1.49% $6.41B /orka-vs-idxx →
NEOG
Neogen Corporation
D 47/100 — 46.9% -0.6% 0.00% $2.58B /neog-vs-idxx →
CLDX
Celldex Therapeutics Inc.
E 29/100 — 87.1% -35.0% -3.52% $2.36B /cldx-vs-idxx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000874716 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), IDEXX Laboratories Inc. (IDXX) reported GAAP revenue of $4.30B (+10.4% vs. FY2024 revenue of $3.90B , and +17.6% cumulative change since FY2023) , GAAP net income of $1.06B, operating cash flow of $1.18B, and free cash flow of $1.06B (+30.8% YoY). On the balance sheet, IDXX closed FY2025 with $3.35B in total assets against $374.8M in total debt (Altman Z-Score: 20.99, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $4.30B $1.06B $1.18B $1.06B $3.35B $374.8M
FY2024 (FY) 2024-12-31 $3.90B $887.9M $929.0M $808.1M $3.29B $449.8M
FY2023 (FY) 2023-12-31 $3.66B $845.0M $906.5M $741.8M $24.96B $5.84B

3. IDXX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IDXX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, IDEXX Laboratories Inc. (NASDAQ: IDXX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $671.64 (+21.85% 1D, market cap $43.42B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, IDXX ranks #72 in composite RQD confidence.

How does IDXX compare to LNTH and ORKA in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), IDXX carries a Roarable B- (70/100 RQD), trailing P/E of 42.8x, gross margin of 61.8%, and ROIC of 29.6%. By comparison, LNTH (Lantheus Holdings Inc.) holds a B+ grade (76/100 RQD, P/E 28.0x, ROIC 20.3%, cap $6.56B) and ORKA (Oruka Therapeutics Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -18.8%, cap $6.41B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while IDXX leads on capital efficiency (29.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IDXX?

Per IDXX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000874716), IDEXX Laboratories Inc. generated $4.30B in revenue (+10.4% YoY), $1.06B in net income, and $1.06B in free cash flow against $3.35B in total assets and $374.8M in total debt. Key quantitative strengths: Strong cash generator (61.8% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IDXX trading relative to its 50-day, 200-day, and 52-week technical levels?

IDXX last traded at $671.64 (+21.85% on volume of 1,977,327 shares), positioning the stock +25.54% above its 50-day simple moving average ($535.00) and +17.71% above its 200-day simple moving average ($570.57). Across its 52-week range of $500.61 to $769.98, IDXX sits at the 63.5% percentile with a 14-day RSI of 50.5 (NEUTRAL RANGE) and an implied next-earnings move of ±5.4% ($635.37 to $707.91).

Direct Sub-Reports: IDXX RQD Cockpit IDXX 12M Forecast IDXX Earnings & Move IDXX Dividends & DRIP IDXX Insiders & 13F IDXX Whale Options IDXX Profit Sankey IDXX News & Why
ROARABLE RATING BRIEF • RQD 70/100 (B-) ✓ SEC XBRL & RQD VERIFIED

IDXX — IDEXX Laboratories Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

IDEXX Laboratories Inc. (IDXX) earns a live Roarable RQD composite score of 70/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $671.64 (+21.85% 1D, market capitalization $43.42B).

  • Fundamental Cash Engine (19/20): Anchored by return on invested capital (ROIC) of 29.6%, gross margin of 61.8%, operating margin of 31.6%, and free cash flow yield of 2.33%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (18/20): Incorporates a 0.89x equity beta, Altman Z-Score of 20.99, Piotroski F-Score of 9/9, and Debt/Equity of 0.23x.

2. Business Model, Unit Margins & SEC Financial Trajectory

IDEXX Laboratories Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry (per the company profile). Specific product lines, customer segments, and revenue mix are — The profile does not describe how the company makes money beyond its sector classification.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), IDEXX Laboratories Inc. (IDXX) reported $4.30B in annual revenue (up from $3.90B in FY2024, +10.4% YoY) and $1.06B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.66B revenue, $845.0M net income) through FY2025, IDXX scaled operating cash flow to $1.18B and free cash flow to $1.06B, backed by $3.35B in total assets against $374.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B- • RQD 70/100): Strong cash generator (61.8% gross margin)—profits are backed by real money, not accounting tricks. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 19/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $500.61 – $769.98 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 42.8x trailing P/E and 31.1x EV/EBITDA against 31.6% operating margins and a 0.89x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), IDXX carries a macro regime beta of 0.89 and gross margin of 61.8%.

  • Key Question #1: Can IDXX sustain or expand its 31.6% operating margin and 29.6% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $4.30B and free cash flow of $1.06B, how will capital allocation balance growth reinvestment against $374.8M in total debt?
  • Key Question #3: How sensitive is IDXX's 39.8x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.89x)?

IDXX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for IDEXX Laboratories Inc. (IDXX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IDXX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IDXX Bull vs. Bear Conversation Board — What's Your Call at $671.64?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IDXX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IDXX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $650.43 (+18.0%)
📌 Pinned Debate

The stock carries a 29.6% ROIC, an Altman Z of 20.99, and a Piotroski F of 9/9, supported by revenue growth from $3.66B to $4.30B a

Here is why I am bullish on IDXX here at $551.21: The stock carries a 29.6% ROIC, an Altman Z of 20.99, and a Piotroski F of 9/9, supported by revenue growth from $3.66B to $4.30B across three fiscal years.. Compare IDXX's 31.6% operating margin and 29.6% ROIC against the rest of Biotechnology: In Vitro & In Vivo Diagnostic Substances. As long as cash conversion holds up, dips toward $523.65 are getting bought.

RetailWhale_TX 🐂 BULL

Both sides have a point here — IDXX's 18/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $468.53 (-15.0%)
Spot @ $551.21

At a P/E (TTM) of 42.8 and EV/EBITDA of 31.1, with a 2.33% FCF yield, the valuation leaves little room for growth to disappoint.

At a P/E (TTM) of 42.8 and EV/EBITDA of 31.1, with a 2.33% FCF yield, the valuation leaves little room for growth to disappoint.. Look at the math on IDXX: paying 42.8x trailing P/E for 29.6% ROIC and 31.6% operating margins leaves zero margin of safety if Biotechnology: In Vitro & In Vivo Diagnostic Substances demand softens. I'd wait for a retest of $485.06 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%